On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


HYB Holding Corp.’s (HYBG) Mediscan Software Improves Ultrasound Techniques, Enhancing Heart Monitoring of COVID-19 Patients

  • Both heart disease, poor metabolic health increase complications of COVID-19, according to health professionals
  • HYB Holding Corp. offers cloud-based software that transforms analog ultrasound 2D images into a digital 3D HD formats that quantify diagnostic capabilities
  • Software can be used to enhance ultrasound images of vital organs, tendons, skin, nerves for use across multiple healthcare markets
  • Provisional patent filed with U.S. Patent and Trademark Office

Epidemiologists observed that people with cardiovascular disease were more than twice as likely to contract severe forms of COVID-19 (https://ibn.fm/wG2j4). HYB Holding (OTC: HYBG), through its Mediscan Inc. subsidiary, offers imaging solutions to ultrasound professionals through cloud-based software that reconstructs analog 2D grayscale visual images into digital 3D high-definition quantifiable formats that can address the critical need to monitor COVID-19 patients for cardiac damage.

While death rates from COVID-19 have dropped significantly in the last six months, cardiovascular disease continues to remain a major predictor of poor outcome. HYBG’s Mediscan software application helps ultrasound technicians derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma while facilitating support for treatment options. The software additionally enables health professionals to monitor the patient’s ongoing progress or regress while documenting compliance with required protocols and procedures.

The company’s software specifically transforms ultrasound analog 2D grayscale images into digital 3D HD format that helps technicians derive data-driven insights into the condition of a patient.  Along with vital organs like the heart, the technique can generate 3D medical images of other parts of the body such as the lungs, tendons, skin and nerves for analysis by emergency medical services (EMS) and other health professionals such as primary care physicians, specialists, technical support staff and sports trainers.

The software is cloud-based and easy to use anywhere there is an internet connection, providing point-of-service medical professionals comparable image quality of CT or X-ray but without the radiation risk and at a far lower cost. Besides upgrading services for healthcare professionals, Mediscan software provides a convenient and comfortable medical experience for patients.

The company plans to make the software available as medical software-as-a-service (SaaS), a widely-used model in the health care industry for clinical information systems, supply chain management, revenue cycle management and billing. Along with operational cost-savings, the SaaS model eliminates the need for external hardware and software configurations as well as technical onsite maintenance. HYBG has a patent application filed with the United States Patent and Trademark Office through its Mediscan subsidiary for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

Flexible and easy-to-use, portable ultrasounds equipped with Mediscan’s application empower health care providers to evaluate, triage and diagnose the effects of heart disease on COVID-19 patients. The increasing demand for early diagnosis and the widening scope of clinical applications create a promising opportunity for Mediscan to fulfill its mission of developing and distributing medical imaging solutions to both long-term care facilities and acute and emergency medical services.

For more information, visit the company’s website at www.MyMediScan.com.

NOTE TO INVESTORS: The latest news and updates relating to HYBG are available in the company’s newsroom at https://ibn.fm/HYBG

From Our Blog

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Releases Record-Breaking Gross Revenue for January 2021

February 26, 2021

Company reports record gross revenues of C$1,089,502 last month “It is truly encouraging to achieve yet another incredible revenue milestone and to start the new year with such vigor and success,” states CEO Record revenue comes during one of slowest e-commerce periods of year, highlighting impact the company has in the plant-based marketplace PlantX Life […]

Rotate your device 90° to view site.